Global Venous Thromboembolism Market Growth, Analysis, Trends, and Industry 2028 In 24 Major Markets
WiseGuyReports.com “Venous Thromboembolism Forecast In 24 Major Markets 2018–2028” report has been added to its Research Database.
Scope of the Report:
The Report on Venous Thromboembolism in 24 Major Markets
Venous thromboembolism (VTE) is a disease in which thrombi or blood clots form in venous blood vessels and either remain at their site of origin or move with the blood flow until they reach a vessel with a diameter small enough to form an occlusion. Clots formed in the large limb or pelvic veins cause a clinical manifestation of VTE called deep vein thrombosis (DVT), while emboli (detached clot fragments) which move to and cause obstruction of pulmonary blood vessels cause a pulmonary embolism (PE). VTE is the third most common cardiovascular disease worldwide (after myocardial infarction and ischaemic stroke), with 2–5% of the global population affected throughout their lives.
Request a Sample Report @ https://www.wiseguyreports.com/sample-request/3316939-epiomic-epidemiology-series-venous-thromboembolism-forecast-in-24
This report provides the current prevalent population for VTE across 24 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Norway, Sweden, Denmark, Finland, Austria, Portugal, Greece, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, DVT and PE patient subsets, as well as those with the main co-morbidities, have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for VTE include:
Cancer
Inflammatory bowel disease
Obesity
Cardiovascular diseases
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilizes a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
- Ability to quantify patient populations in global VTE market to target the development of future products, pricing strategies and launch plans.
- Further insight into the prevalence of the subdivided types of VTE and identification of patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Better understanding on the impact of specific co-morbid conditions on the prevalent population of VTE patients.
- Identification of VTE patient sub-populations that require treatment.
- Better understanding of the specific markets that have the largest number of VTE patients.
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3316939-epiomic-epidemiology-series-venous-thromboembolism-forecast-in-24
Major Key Points in Table of Content:
LIST OF TABLES AND FIGURES
INTRODUCTION
CAUSE OF THE DISEASE
RISK FACTORS & PREVENTION
DIAGNOSIS OF THE DISEASE
VARIATION BY GEOGRAPHY/ETHNICITY
DISEASE PROGNOSIS & CLINICAL COURSE
KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
TOP-LINE PREVALENCE FOR ADDISON’S DISEASE
FEATURES OF ADDISON’S DISEASE PATIENTS
COMORBIDITIES OF ADDISON’S DISEASE PATIENTS
ABBREVIATIONS USED IN THE REPORT
OTHER BLACK SWAN SERVICES & SOLUTIONS
REPORTS & PUBLICATIONS
ONLINE EPIDEMIOLOGY DATABASES
ONLINE PHARMACEUTICAL PRICING DATABASE
REFERENCES
APPENDIX
Continuous...
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Scope of the Report:
The Report on Venous Thromboembolism in 24 Major Markets
Venous thromboembolism (VTE) is a disease in which thrombi or blood clots form in venous blood vessels and either remain at their site of origin or move with the blood flow until they reach a vessel with a diameter small enough to form an occlusion. Clots formed in the large limb or pelvic veins cause a clinical manifestation of VTE called deep vein thrombosis (DVT), while emboli (detached clot fragments) which move to and cause obstruction of pulmonary blood vessels cause a pulmonary embolism (PE). VTE is the third most common cardiovascular disease worldwide (after myocardial infarction and ischaemic stroke), with 2–5% of the global population affected throughout their lives.
Request a Sample Report @ https://www.wiseguyreports.com/sample-request/3316939-epiomic-epidemiology-series-venous-thromboembolism-forecast-in-24
This report provides the current prevalent population for VTE across 24 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Norway, Sweden, Denmark, Finland, Austria, Portugal, Greece, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, DVT and PE patient subsets, as well as those with the main co-morbidities, have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for VTE include:
Cancer
Inflammatory bowel disease
Obesity
Cardiovascular diseases
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilizes a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
- Ability to quantify patient populations in global VTE market to target the development of future products, pricing strategies and launch plans.
- Further insight into the prevalence of the subdivided types of VTE and identification of patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Better understanding on the impact of specific co-morbid conditions on the prevalent population of VTE patients.
- Identification of VTE patient sub-populations that require treatment.
- Better understanding of the specific markets that have the largest number of VTE patients.
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3316939-epiomic-epidemiology-series-venous-thromboembolism-forecast-in-24
Major Key Points in Table of Content:
LIST OF TABLES AND FIGURES
INTRODUCTION
CAUSE OF THE DISEASE
RISK FACTORS & PREVENTION
DIAGNOSIS OF THE DISEASE
VARIATION BY GEOGRAPHY/ETHNICITY
DISEASE PROGNOSIS & CLINICAL COURSE
KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
TOP-LINE PREVALENCE FOR ADDISON’S DISEASE
FEATURES OF ADDISON’S DISEASE PATIENTS
COMORBIDITIES OF ADDISON’S DISEASE PATIENTS
ABBREVIATIONS USED IN THE REPORT
OTHER BLACK SWAN SERVICES & SOLUTIONS
REPORTS & PUBLICATIONS
ONLINE EPIDEMIOLOGY DATABASES
ONLINE PHARMACEUTICAL PRICING DATABASE
REFERENCES
APPENDIX
Continuous...
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Comments
Post a Comment